A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” mutant of Bcr-Abl

The second generation of Bcr-Abl inhibitors nilotinib, dasatinib, and bosutinib developed to override imatinib resistance are not active against the T315I ‘gatekeeper’ mutation. Here we describe a Type-II T315I inhibitor GNF-7, based upon a 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one scaffold whic...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Choi, Hwan Geun, Ren, Pingda, Adrian, Francisco, Sun, Fangxian, Lee, Hyun Soo, Wang, Xia, Ding, Qiang, Zhang, Guobao, Zhang, Yongping, Liu, Yi, Tuntland, Tove, Warmuth, Markus, Manley, Paul W., Mestan, Jürgen, Gray, Nathanael S, Sim, Taebo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2010
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4134510/
https://ncbi.nlm.nih.gov/pubmed/20604564
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/jm901808w
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller